Biliary tract cancer

12 · 20 / page

Ask MedXY AI

Latest news

Tag

GastroenterologyBiliary tract cancercisplatin

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY|Jul 12, 2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

GastroenterologyBiliary tract cancer

Biliary tract cancer

Latest news

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

Zanidatamab Shows Durable Activity and Pain Benefit in HER2‑Positive Metastatic Biliary Tract Cancer: Final HERIZON‑BTC‑01 Results

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer

Efficacy of Liposomal Irinotecan Plus 5-FU/LV in Previously Treated Biliary Tract Cancer: Insights from Pooled NIFTY and NALIRICC Trials

International Trends in Biliary Tract Cancer Mortality from 2000 to 2022: A Comprehensive WHO Database Analysis